Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Research Abstract Details
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Publishing Authors By Initials
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Journal Published:
PUBLICATION TYPE: Letter
Journal: Bone marrow transplantation
VOLUME: 40
Page Numbers: 913-4
Journal Abbreviation: Bone Marrow Transplant.
ISSN: 0268-3369
DAY: 27
MONTH: 08
YEAR: 2007
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 8702459
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.
AFFILIATION:
Country: England
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Bone Marrow Transplant
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan Related Publications